Sodium Carbonate → N-(6-(6-chloro-5-(3-(difluoromethoxy)phenylsulfonamido)pyridin-3-yl)-3-(pyridin-3-yl)imidazo[1,2-b]pyridazin-2-yl)acetamide

HRID 1162494노트

반응식

HRID 1162494 반응식
[Cl:1][C:2]1[N:7]=[CH:6][C:5]([C:8]2[CH:9]=[CH:10][C:11]3[N:12]([C:14](I)=[C:15]([NH:17][C:18](=[O:20])[CH3:19])[N:16]=3)[N:13]=2)=[CH:4][C:3]=1[NH:22][S:23]([C:26]1[CH:31]=[CH:30][CH:29]=[C:28]([O:32][CH:33]([F:35])[F:34])[CH:27]=1)(=[O:25])=[O:24].[N:36]1[CH:41]=[CH:40][CH:39]=[C:38](B(O)O)[CH:37]=1.C(=O)([O-])[O-].[Na+].[Na+]>[Pd+2].ClC1C=C[C-](P(C2C=CC=CC=2)C2C=CC=CC=2)C=1Cl.[C-]1(P(C2C=CC=CC=2)C2C=CC=CC=2)C=CC=C1.[Fe+2].O1CCOCC1>[Cl:1][C:2]1[N:7]=[CH:6][C:5]([C:8]2[CH:9]=[CH:10][C:11]3[N:12]([C:14]([C:38]4[CH:37]=[N:36][CH:41]=[CH:40][CH:39]=4)=[C:15]([NH:17][C:18](=[O:20])[CH3:19])[N:16]=3)[N:13]=2)=[CH:4][C:3]=1[NH:22][S:23]([C:26]1[CH:31]=[CH:30][CH:29]=[C:28]([O:32][CH:33]([F:35])[F:34])[CH:27]=1)(=[O:25])=[O:24]

참가 물질

6

반응물 3

HCID 10340Sodium CarbonateHCID 27343783-Pyridinylboronic acidHCID 57749431N-(6-(6-chloro-5-(3-(difluoromethoxy)phenylsulfonamido)pyridin-3-yl)-3-iodoimidazo[1,2-b]pyridazin-2-yl)acetamide

생성물 1

HCID 44124987N-(6-(6-chloro-5-(3-(difluoromethoxy)phenylsulfonamido)pyridin-3-yl)-3-(pyridin-3-yl)imidazo[1,2-b]pyridazin-2-yl)acetamide

시약·촉매·용매 2

HCID 178478230HCID 178478230, 화합물촉매HCID 312751,4-Dioxane용매

반응 조건

온도
90 °C

실험 절차

A sealable vial was charged with N-(6-(6-chloro-5-(3-(difluoromethoxy)phenylsulfonamido)pyridin-3-yl)-3-iodoimidazo[1,2-b]pyridazin-2-yl)acetamide (27.0 mg, 42.5 μmol), 3-pyridylboronic acid (6.27 mg, 51.0 μmol), and dichloro 1,1′-bis(diphenylphosphino)ferrocene palladium(II) (2.36 mg, 4.25 μmol). The vial was sealed and 1,4-dioxane (1 mL) was added under positive N2 flow. Then an aqueous solution of sodium carbonate (1.9 M, 89.5 μl, 170 μmol) was added via syringe. The resulting solution was sparged with N2 for 10 minutes, then heated at 90° C. for 18 h. The solution was cooled to rt and directly absorbed onto a 5 g silica loading cartridge and passed through a Redi-Sep® pre-packed silica gel column (Teledyne Isco, Lincoln, Nebr.) (12 g) using a gradient of 1% MeOH in CH2Cl2 to 10% MeOH in CH2Cl2 to afford the title compound N-(6-(6-chloro-5-(3-(difluoromethoxy)phenylsulfonamido)pyridin-3-yl)-3-(pyridin-3-yl)imidazo[1,2-b]pyridazin-2-yl)acetamide as a yellow solid. LCMS (ESI positive ionization) m/z: 586 (M+1); 1H NMR (400 MHz, MeOH) δ ppm 2.18 (s, 3H); 6.81 (t, J=73.11 Hz, 1H); 7.32-7.40 (m, 1H); 7.48 (t, J=8.02 Hz, 1H); 7.53-7.57 (m, 1H); 7.58-7.63 (m, 1H); 7.67 (dd, J=7.87, 5.04 Hz, 1H); 7.90 (d, J=9.49 Hz, 1H); 8.15 (d, J=9.49 Hz, 1H); 8.47 (d, J=8.02 Hz, 1H); 8.60 (d, J=3.52 Hz, 1H); 8.64 (d, J=2.25 Hz, 1H); 8.77 (d, J=2.25 Hz, 1H); 8.97 (s, 1H).

후처리

  1. customThe vial was sealed
  2. customThe resulting solution was sparged with N2 for 10 minutes
  3. temperatureThe solution was cooled to rt
  4. customdirectly absorbed onto a 5 g silica loading cartridge

출처 및 근거

ORD 기록
ord-220279c15f1244469cbe71cea3d8c299
출처 데이터셋
uspto-grants-2010_10
특허 번호
US07820665B2

반응 노트

불러오는 중…